Company Description
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts.
Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics.
The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities.
The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb’s antibody discovery platform.
OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 114 |
| CEO | Matthew Foehr |
Contact Details
Address: 5980 Horton Street, Suite 600 Emeryville, California 94608 United States | |
| Phone | 510 250 7800 |
| Website | omniab.com |
Stock Details
| Ticker Symbol | OABI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001846253 |
| CUSIP Number | 68218J103 |
| ISIN Number | US68218J1034 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Matthew W. Foehr | President, Chief Executive Officer and Director |
| Kurt A. Gustafson | Executive Vice President of Finance and Chief Financial Officer |
| Charles S. Berkman J.D. | Chief Legal Officer and Secretary |
| Cia McCaffrey | Vice President of People and Talent |
| Dr. Bill Harriman Ph.D. | Senior Vice President of Antibody Discovery |
| Dr. Christel Iffland Ph.D. | Senior Vice President of Antibody Technologies |
| Dr. Yasmina Noubia Abdiche Ph.D. | Senior Vice President of Exploratory Research |
| Donna Ventura CPA | Senior Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2025 | SCHEDULE 13G | Filing |
| Jun 18, 2025 | 8-K | Current Report |
| Jun 6, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2025 | 8-K | Current Report |